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A meta-analysis was performed to quantify the magnitude and nature of the association
between adjuvant chemotherapy and performance on a range of cognitive domains among
breast cancer patients. A total of 27 studies (14 cross-sectional, 8 both cross-sectional and
prospective, and 5 prospective) were included in the analyses, involving 1562 breast can-
cer patients who had undergone adjuvant chemotherapy and 2799 controls that included
breast cancer patients who did not receive adjuvant chemotherapy. A total of 737 effect
sizes (Cohen’s d ) were calculated for cross-sectional and prospective longitudinal studies
separately and classified into eight cognitive domains.The mean effect sizes varied across
cross-sectional and prospective longitudinal studies (ranging from−1.12 to 0.62 and−0.29
to 1.12, respectively). Each cognitive domain produced small effect sizes for cross-sectional
and prospective longitudinal studies (ranging from −0.25 to 0.41). Results from cross-
sectional studies indicated a significant association between adjuvant chemotherapy and
cognitive impairment that held across studies with varied methodological approaches. For
prospective studies, results generally indicated that cognitive functioning improved over
time after receiving adjuvant chemotherapy. Greater cognitive impairment was reported
in cross-sectional studies comparing chemotherapy groups with healthy control groups.
Results suggested that cognitive impairment is present among breast cancer patients irre-
spective of a history of chemotherapy. Prospective longitudinal research is warranted to
examine the degree and persisting nature of cognitive impairment present both before
and after chemotherapy, with comparisons made to participants’ cognitive function prior
to diagnosis. Accurate understanding of the effects of chemotherapy is essential to enable
informed decisions regarding treatment and to improve quality of life among breast cancer
patients.
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INTRODUCTION
Breast cancer has been reported as the second most commonly
diagnosed cancer (1). Adjuvant chemotherapy increases the sur-
vival rate in breast cancer patients and is currently administered
to up to 60% of patients below the age of 60 years (2). Indeed,
it was reported that the 5-year survival rates after breast cancer
diagnosis were 89.2% during 2004–2010, and it was estimated
that almost 2.9 million women were currently living with breast
cancer in the United States in 2010 (1). Hence, quality of life has
become an important issue for breast cancer survivors. Although
its medical efficacy is undeniable, the negative effects of adju-
vant chemotherapy on cognitive functioning have been reported
by some breast cancer patients, even years after treatment in
some cases (3–9). To support informed decision making, it is
important to understand the magnitude and specific areas of cog-
nitive impairment that breast cancer patients may experience after
adjuvant chemotherapy.
An increasing number of studies have examined the effects of
adjuvant chemotherapy for breast cancer on cognitive functioning
(10–13). More specifically, levels of cognitive functioning between
women with a history of chemotherapy and their comparison
in cross-sectional studies (i.e., termed “cognitive impairment”)
and changes in levels of cognitive functioning pre- and post-
chemotherapy in prospective longitudinal studies (i.e., termed
“cognitive decline”) have been investigated. A recent meta-analysis
suggests that breast cancer patients exposed to adjuvant therapy
perform worse than comparison groups (e.g., cancer patients who
do not receive adjuvant therapy, non-cancer comparison group)
or normative data (11). However, these studies have not found
consistent evidence of impairment within a specific neurocog-
nitive domain. For example, neuropsychological outcomes have
varied according to characteristics of the breast cancer sample
studied, such as stage of tumor, time since treatment or diagnosis,
menopausal status, and the use of tamoxifen or other anti-estrogen
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drugs, age, education level, and the amount of chemotherapy that
patients received (10, 11, 14, 15). In addition, different control
groups (e.g., pre-chemotherapy baseline, healthy control, or cancer
control) have been used in these studies. Such inconsistencies make
comparison between studies difficult since post-chemotherapy
cognitive impairment may be observed only among a particular
subgroup of breast cancer patients.
Furthermore, the definition of cognitive impairment/decline
lacks consistency across studies. For example, it has been defined
as a 1-SD decline (16), a 1.96 SDs decline (17), a 2 SDs (18) decline,
or a 1.64 z-score decline (19) from pre- to post-chemotherapy. In
cross-sectional studies, cognitive impairment has been typically
defined as a score at least 2 SDs below the mean of a healthy control
group on a test index (6, 20–23) or of the relevant published norm
(24). Other studies categorized levels of impairment into mild (1
SD below on one test index) and moderate (2 SDs below on one
test index) as compared to the relevant published norm (25). Cog-
nitive impairment was also defined using the mean z-score of the
relevant published test norm with various SDs, ranging from 1.4
SDs (26) to 2.0 SDs (27). The score at or below the fifth percentile
of the control group was also used to define an overall impair-
ment in some studies (5, 22). Consequently, evidence of post-
chemotherapy cognitive impairment/decline among breast cancer
patients may vary according to the definition employed in studies.
Overall, it must be noted that there is no widely accepted statistical
convention or cut-off in determining clinically significant declines
or impairments in cognitive functioning. However, Zakzanis (28)
proposed that a Cohen’s d effect size greater than±3.0 is an appro-
priate marker of clinical significance in determining the sensitivity
of neuropsychological tests.
Given the inconsistencies in the literature, the use of a single,
universal unit (e.g., effect size) is ideal to synthesize findings and
form a consensus on the negative effects of adjuvant chemotherapy
on cognitive functioning among breast cancer patients. Indeed,
four meta-analytic reviews have been conducted to date (10, 11,
14, 15). Table 1 summarizes the cognitive domains examined by
each review.
The first meta-analysis published by Falleti et al. examined
the nature and severity of cognitive impairment associated with
adjuvant chemotherapy using five cross-sectional studies and one
prospective longitudinal study (10). Analysis of cross-sectional
studies revealed that the chemotherapy group performed worse
than controls in all six cognitive domains (see Table 1). Of these,
significant cognitive impairment was observed in the domains
of spatial ability (d =−0.48) and language (d =−0.41). The
authors also reported statistically significant logarithmic relation-
ships between larger effect sizes (i.e., more significant cognitive
impairment) and shorter time since last chemotherapy, greater
proportions of patients currently treated with tamoxifen, and
younger patient age. Younger patients may have been treated with
tamoxifen more often than older patients, although this was not
examined. Regardless, the results suggest that specific subsets of
breast cancer patients may be more vulnerable to the cognitive
effects of chemotherapy. In contrast, analysis of a prospective lon-
gitudinal study showed a wide range of positive effect sizes (i.e.,
improvement) across cognitive domains (d = 0.11 in motor func-
tion to d = 1.09 in attention). It was concluded that the magnitude
of impairment in each domain is moderated by particular variables
(e.g., age, time since last chemotherapy and chemotherapy type)
and influenced by study design (cross-sectional vs. prospective).
However, only one prospective longitudinal study was included in
this early meta-analysis.
The aim of the second meta-analysis, published in 2005 by
Jansen et al. (13), was to examine the effects of post-chemotherapy
cognitive impairment among cancer patients in eight cognitive
domains (see Table 1). Sixteen studies were included in this
Table 1 | Meta-analytic studies and examined cognitive domains (k =number of comparisons within a meta-analysis, N = combined number of
participants).
Cognitive domain Authors (reference, K=Study N )
Falleti et al.
[(10), K=6]
Jansen et al.
[(13), K=16]a
Stewart et al.
[(15), K=7]
Jim et al.
[(11), K=17]
Cross-sectional Prospective Both cross-sectional and prospective
Attention k=36, N=330 k=3 N=830 k=14, N=366 k=21
Executive function k=31, N=330 k=5 N=996 Working memory: k=15, N=266 k=19
Information processing speed N/A N=617 k=23, N=336 k=11
Motor speed/function k=12, N=275 k=2 N=816 k=16, N=325 k=11
Verbal ability/language k=3, N=70 N=795 k=12, N=372 k=15
Visuospatial ability/skill k=5, N=153 k=1 N=782 k=10, N=344 k=9
Memory k=35, N=330 k=4 N/A N/A N/A
Verbal memory N/A N=902 N/A k=23
Visual memory N/A N=591 N/A k=21
Short-term memory N/A N/A k=18, N=328 N/A
Long-term Memory N/A N/A k=21, N=364 N/A
aK=9 focusing on breast cancer.
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analysis and, although not all, the majority of those studies (k = 9)
focused on breast cancer patients. It also aimed to differentiate the
effect sizes by type of control data: normative data, control group
data, or chemotherapy patients’ baseline data. Only visual mem-
ory showed significant impairment among chemotherapy patients
across all comparison types. When the neuropsychological test
scores of chemotherapy patients were compared with norma-
tive data, significant effect sizes (d =−0.52 to d =−0.78) were
found in four cognitive domains (i.e., executive function, infor-
mation processing speed, verbal memory, and visual memory).
Conversely, a significant, but low level of impairment in language
and verbal memory was identified when scores of chemother-
apy patients were compared with those of healthy matched con-
trols. However, no significant differences were identified on these
domains when chemotherapy patients were compared with con-
trol patients treated with local therapy or with their own baseline
scores. The analyses conducted only with breast cancer patients
showed similar results (i.e., effect size, significance). Hence, the
degree of impairment in each cognitive domain associated with
chemotherapy varied, depending on control group characteris-
tics. Nevertheless, the potential moderating role of control group
type was not formally examined.
Stewart et al.’s (15) meta-analysis in 2006 examined seven stud-
ies (with one longitudinal), including the six examined by Falleti
et al. (10). Of the eight cognitive domains evaluated (see Table 1),
statistically significant small to medium weighted pooled effect
sizes (d =−0.24 to−0.37) were found in all domains except simple
attention and processing speed. The largest effect sizes were found
in language (d =−0.37) and short-term memory (d =−0.31).
However, the fail-safe numbers were smaller than recommended.
It was concluded that cognitive impairment was subtle and/or only
seen among a particular subgroup of women. The authors did not
differentiate the effect sizes by type of control group or study
design, and this may explain the relatively smaller grand mean
effect sizes found in this review than those found in previous
reviews. In addition, in this meta-analysis studies were manu-
ally removed from analyses for each cognitive domain to achieve
homogeneity. Thus, the results may not be representative of the
broader breast cancer population.
In the most recent meta-analytic review by Jim et al. in 2012
(11), cognitive functioning in the post-treatment period (i.e., at
least 6 months post-therapy) among breast cancer patients was
examined. It also examined demographic and clinical moderators
of cognitive impairment in patients with breast cancer, includ-
ing age, education, time since chemotherapy, and treatment with
endocrine therapy. The authors included 17 studies, which var-
ied in type of control group: patients’ pre-chemotherapy base-
line (k = 4); patients who received local therapy (i.e., radiation,
surgery) or endocrine therapy (k = 6); patients without cancer
(k = 3); two types of control group (pre-chemotherapy base-
line and local or endocrine therapy only, k = 2); and all three
types of control group (k = 2). Overall, chemotherapy patients
performed worse in the domains of verbal ability (g =−0.19,
p< 0.01) and visuospatial ability (g =−0.27, p< 0.01). As post-
chemotherapy cognitive impairment in these domains depended
on types of comparisons (i.e., type of control group), type of con-
trol group was reported as a likely moderating factor, although
this was not formally tested. Thus, it remains unclear whether
the type of control group significantly moderates the magnitude
of post-chemotherapy cognitive impairment among breast can-
cer patients. In addition, no demographic or clinical factors were
found to moderate observed cognitive impairment in verbal ability
or visuospatial ability (all p> 0.05). This may be partly due to their
inclusion criteria being at least 6 months post-treatment where
any cognitive impairment experienced may have diminished with
time. Alternatively, as significant moderators were reported by Fal-
leti et al. (10), results may need to be analyzed separately by study
design (cross-sectional vs. prospective longitudinal studies). In the
current meta-analysis, moderating factors are examined for cross-
sectional studies and prospective longitudinal studies separately.
While there is a general consensus in these meta-analytic
reviews regarding the adverse effects of chemotherapy on cognitive
functioning among breast cancer patients, their specific findings
varied. For example, while some cognitive domains (e.g., language)
have more consistently been identified as affected functions, the
results have not been firmly conclusive. This may be due to the
small number of studies included, and/or a strict inclusion criteria
employed, that is, at least 6 months post-treatment in Jim et al.
(11). In addition, it has been suggested that grand mean effect
sizes may obscure the detection of subtle cognitive decline in a
vulnerable subgroup (10, 27). Hence, identification of factors that
moderate the magnitude of post-chemotherapy cognitive impair-
ment is important. Indeed, as discussed above, Falleti et al. (10)
reported moderators (e.g., time since treatment, younger age, cur-
rent tamoxifen use), but these results were inconsistent with Jim
et al.’s (11) results. Furthermore, although suggested (11, 14), the
moderating role of type of controls has never been tested formally.
Some studies (3, 17, 29, 30) have reported that psychologi-
cal factors such as fatigue, depression, and anxiety can have a
negative impact on cognitive functioning in cancer patients. Pre-
vious studies that examined the role of chemotherapy in cognitive
functioning typically either excluded breast cancer patients with
past and/or current psychiatric disorders (5, 8, 17, 18, 20–24, 27,
31–36), found no significant group differences in emotional func-
tioning (9, 12, 37), or statistically controlled for these factors
(7, 26, 38). Indeed, the role of psychological factors in post-
chemotherapy cognitive functioning was not examined in per-
vious meta-analyses. Consequently, the current meta-analysis did
not include psychological factors as moderating factors.
The current meta-analytic review includes a broader selection
of studies compared to previous reviews with two study aims.
First, it aimed to identify the magnitude of cognitive impairment
among breast cancer patients treated with adjuvant chemother-
apy in eight cognitive domains: attention; executive function;
long-term (delayed) memory; short-term memory; speed of pro-
cessing; language; visuospatial; and motor function. The selection
of domains was based on clinical practice and neuropsycholog-
ical assessment literature (39–41). The categories of short- and
long-term memories were deemed more appropriate than ver-
bal and visual memories, given that the effect of chemotherapy
is more global or diffuse in nature rather than localized in one
hemisphere (42). Second, this review aimed to identify factors
that moderate the magnitude of cognitive impairment among
breast cancer patients treated with chemotherapy. As discussed
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previously, the findings of moderating factors in previous meta-
analyses have been mixed. However, this may be partly because
cross-sectional studies and prospective longitudinal studies have
different study focuses, i.e., cognitive impairment and cognitive
decline, respectively. Indeed, study design (e.g., cross-sectional
vs. prospective) has been suggested to moderate the results (10,
11). Thus, the moderating effects of time since treatment, type
of control group, and patients’ demographic characteristics (age
and education level) were examined separately for cross-sectional
studies and prospective longitudinal studies via meta-regression.
Identification of moderators would advance knowledge of risk
factors for experiencing cognitive impairment associated with
chemotherapy among breast cancer patients.
METHOD
SEARCH STRATEGY
Three search strategies were employed to identify suitable pub-
lished studies for inclusion in the meta-analysis. First, nine com-
puterized databases were searched: PsychINFO, ProQuest Psy-
chology, PsycARTICLES, PubMed/MEDLINE, CINAHL, Web of
Science ISI, Scopus, Cambridge Scientific Abstracts, and Google
Scholar. The keywords used to search the databases included:
breast cancer, breast neoplasms, chemotherapy, adjuvant chemother-
apy, treatment effects, cognition, cognitive, cognitive functioning,
neurocognitive, neuropsychological, neuropsychological tests, cancer
treatment, and cognitive impairment. Second, the reference lists of
published studies collected, and previous meta-analyses and nar-
rative reviews of the topic (10, 11, 14, 15) were scanned to locate
further studies not found in the database searches. Third, manual
searches of relevant journals were conducted to identify studies,
including Clinical Breast Cancer, Journal of Clinical Oncology,
Cancer, Journal of Neuro-Oncology, Neuropsychologia, Journal
of Clinical and Experimental Neuropsychology, Psycho-Oncology,
Neuro-Oncology, Neuro-Oncology Practice, and Acta Oncologia.
The search was inclusive of studies published up to August 2014.
INCLUSION CRITERIA
To be included in the meta-analysis, studies had to satisfy the
following criteria:
1. Studies report objective neuropsychological data regard-
ing women with breast cancer who underwent adjuvant
chemotherapy using either cross-sectional (i.e., comparison
groups) or prospective (i.e., patients assessed before and after
chemotherapy) designs;
2. For cross-sectional studies, the comparison group consisted
of healthy individuals or breast cancer patients not receiving
chemotherapy (e.g., local therapy only);
3. For prospective longitudinal studies, patients were assessed
before the commencement of chemotherapy and at least one
time point after the completion of chemotherapy;
4. At least one validated measure of neuropsychological function-
ing was used. Studies reporting data from screening measures
only (e.g., Mini Mental Status Exam, High Sensitivity Cognitive
Screen) were excluded;
5. The results were published in a peer-reviewed journal and in
English;
6. Each study reported original group data – the data did not
relate to individual case-studies, reviews, commentaries or
meta-analyses; and
7. The results presented were sufficient to calculate effect sizes
(i.e., means and SDs, t -values, F-values, p-values, or r-values).
Data extracted from studies included neuropsychological test
data (i.e., mean scores, SDs, and sample size), study design char-
acteristics (i.e., type of control group and timing of assessments),
and participant characteristics (i.e., age, education, intelligence
assessment, and time since chemotherapy). When sufficient infor-
mation was not present to calculate effect sizes, an attempt was
made to contact authors to obtain the required information. Nine-
teen authors were contacted to obtain additional information, and
one author replied with sufficient data.
STUDY DESIGN AND CLASSIFICATION
As shown in Figure 1, a total of 27 studies were included in the
meta-analysis, including 14 reporting cross-sectional data only,
eight reporting both cross-sectional and prospective data, and five
reporting prospective data only.
Effect sizes were calculated separately for cross-sectional and
prospective designs. For studies reporting cross-sectional data,
samples were grouped according to treatment type and dosage
and comparison groups. Two studies (5, 26) included two
groups of chemotherapy patients of standard-dose and high-
dose chemotherapy, and one study (38) included two groups
of chemotherapy patients, namely, those receiving chemother-
apy alone and those receiving chemotherapy and tamoxifen. For
these studies, two sets of effect sizes were calculated, one for each
chemotherapy group contrasted against the comparison group.
Four studies (33, 34, 38, 43) included cross-sectional data on cog-
nitive functioning at multiple time points after the completion of
chemotherapy [e.g., 5–6 months and 1 year follow-up for Collins
et al. (33)] for chemotherapy and comparison groups. For these
studies, a set of effect sizes was calculated at each time point,
with time after completion of chemotherapy recorded for analyses
of moderators. For cross-sectional studies included in the meta-
analysis, a range of comparison groups were used to compare cog-
nitive functioning of chemotherapy patients. Comparison groups
included healthy controls (12 studies), breast cancer patients not
receiving any treatment (one study), breast cancer patients receiv-
ing adjuvant endocrine/hormonal treatment only (four studies),
and breast cancer patients receiving local therapy (i.e., surgery
and/or radiation) only (11 studies). The type of comparison group
(i.e., healthy vs. patient comparisons) was examined as a potential
moderator of effect sizes using a meta-analytic regression ran-
dom effects model (44, 45). Four cross-sectional studies (8, 32, 37,
43) included two comparison groups (i.e., healthy controls and
patient controls) to contrast the cognitive functioning of patients
receiving chemotherapy. For these studies, two sets of effect sizes
were calculated, one for each control group contrasted against the
chemotherapy group.
NEUROPSYCHOLOGICAL MEASURES
A total of 81 independent neuropsychological measures were
used across the studies included in the meta-analysis. These
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LITERATURE SEARCH
Databases: PsycINFO, ProQuest Psychology, PsycARTICLES, PubMed/MEDLINE, CINAHL, Web of Science 
ISI, Scopus, Cambridge Scientific Abstracts and Google Scholar
Key words: breast cancer, breast neoplasms, chemotherapy, adjuvant chemotherapy, treatment effects, cognition, 
cognitive, cognitive functioning, neurocognitive, neuropsychological, neuropsychological tests, cancer treatment, 
and cognitive impairment
Search results combined (K = 3657)
Scanning of the reference lists of published studies collected, and previous meta-
analyses and narrative reviews of the topic (1-4).
Included (k = 9)
Manual searches of relevant journals: Clinical Breast Canc; Journal of Clinical Oncology; Cancer;
Journal of Neuro-Oncology; Neuropsychologia; Journal of Clinical and Experimental Neuropsychology; 
Psycho-Oncology; Acta Oncologia; Neuro-Oncology; and Neuro-Oncology Practice.
Search results combined (k = 27)
Included (k = 1)
Contact authors of studies that were excluded due to 
insufficient data (k = 19) 
Included (k = 2)
Included (k = 15)
Inclusion Criteria: Cross-sectional comparing 
chemotherapy patients with healthy or cancer 
controls; prospective longitudinal studies with pre-
and post-chemotherapy assessment; at least one valid 
measure of neuropsychological functioning; 
published in aa peer-reviewed journal and in English; 
reporting original group data; the results presented 
were sufficient to calculate effect sizes
FIGURE 1 | Flow diagram: literature search and selection.
neuropsychological measures were categorized into eight separate
cognitive domains according to the primary cognitive function
each test is purported to assess based on clinical practice and neu-
ropsychological assessment literature (39–41). Table 2 displays the
eight cognitive domains and the individual neuropsychological
measures assigned to each category. Although a single neuropsy-
chological measure may tap multiple cognitive functions, an effort
was made to assign each individual measure to a single cognitive
domain according to a primary domain of cognitive functioning as
specified by major test compendiums. This approach was adopted
to minimize over-inflation and violation of the independence
of mean effect sizes in the meta-analysis. Tests of homogeneity
of effect sizes were performed within each domain of cognitive
functioning to assess whether the neuropsychological tests were
measuring common parameters.
DATA COLLECTION AND EFFECT SIZE PROTOCOL
Twenty-seven studies met inclusion criteria for the meta-analysis.
The following approach was adopted to calculate effect sizes:
1. Calculation of individual effect sizes (d) and correspond-
ing variances for each neuropsychological test outcome in
each study. For cross-sectional studies, this was the differ-
ence between chemotherapy and control group scores, and
for prospective longitudinal studies, this was the difference
between pre- and post-chemotherapy scores;
2. Calculation of weighted mean effect size for each study using
fixed and random effects models;
3. Calculation of weighted mean effect sizes for each cogni-
tive domain across studies using fixed and random effects
models;
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Table 2 | Cognitive domains assigned to the neuropsychological measures.
Cognitive domain Neuropsychological measuresa
Attention Arithmetic (WAIS),2,5,17,22,25,27 CNS-vital signs (flexibility, working memory),6 continuous performance test (CPT),1,2 D2 test
(GZ-F),11,18,19,23 digit span (forwards and backwards, WAIS and WMS),2,5,6,10,11,14,15,17,18,19, 21,22,23,24,25,26,27 digit symbol
(WAIS),1,4,5,6,7,9,10,11,12,15,18,22,23,25,26 paced auditory serial addition test (PASAT),4,5,6,22 RBANS attention,13 spatial span (WAIS
and WMS),5,10, 14,15, 22 test of everyday attention (TEA; auditory elevator9, telephone search24), test battery for attentional
performance (TAP; Alertness,19 Go/No-Go19), trail making test A,1,4,5,6,7,9,10,11,12,15,17,18, 19,20,22,23,25,26,27 visual elevator,24 visual
span (WAIS),19 and visual attention test20
Executive function Consonant trigrams,5,22 controlled oral word association,6,17,26 D-KEFS Sorting Task,24 IED Stage 5,17,27 Regensburg word
fluency test (RWT),11,19 trail making test B,1,4,5, 6,7,10,11,12,15,17,18,19,20,22,23,25,26,27 stroop color-word,4,7, 8,12,13,14,16,18,20,21,23,24
verbal fluency,1,4,5, 6,7,10,11,12,15,16,18,19,20,22,23,24,25 and Wisconsin Card Sorting Test5,17,22,27
Long-term memory 15-Word learning test (delayed and recognition),16 Benton facial recognition test,17,27 Benton visual retention total errors,17,27
brief visuospatial memory test (BVMT) revised (delayed),6 California verbal learning test (delayed recall and
recognition),1,4,5,7,10,15,22 CNS-vital signs (visual and verbal, delayed),6 family pictures (WMS; delayed and recognition),2,5,22
logical memory (WMS; delayed and recognition),1,4,5,11,14,21,22 Hopkins verbal learning test revised (delayed recall),6,12,26
RBANS delayed memory,13 Rey auditory verbal learning test (delayed recall and recognition),3,5,14,17, 18,19,21, 22,23, 24,27 Rey
complex figure test (delayed recall and recognition),3,4,12,14,17,19,20,21, 23,27 visual verbal learning test (delayed and total),8 and
visual reproduction (WMS; delayed and recognition)1,7,10,15,18, 20,24
Short-term memory 4WSTM,3 15-word learning test (immediate recall),16 auditory consonant trigrams test,6 Benton visual retention test
revised,6,17,27 BVMT revised (total),6 California verbal learning test (immediate recall),1,4,5,7,15,22 CNS-vital signs (visual and
verbal, immediate),6 Hopkins verbal learning test revised (total),6,26 letter digit coding test,8 letter digit substitution test,16
letter-number sequencing (WAIS),2,5,6,14,17,20,21, 22,27 logical memory (WMS; immediate),1,4,11,14 RBANS immediate
memory,8,13 Rey auditory verbal learning test (immediate recall),3,5,14,17,19,20,21,22,23 Rey complex figure test (immediate
recall),3,12,14,18, 21 and visual reproduction (WMS; immediate)1,4,7,10, 15,18,20,24
Speed of processing 2 and 7 test,15 Bourdon-Wiersma dot Cancelation test,9 CNS-vital signs (processing speed, reaction time),6 Fepsy (binary
choice, visual reaction, and visual searching),18,23 letter cancellation,14,21 letter digit substitution test,16 reaction time,4,20
symbol digit modalities test,24 symbol search (WAIS),5,6,22 and test battery for attentional performance (TAP; simple reaction
time)4,19
Language Boston Naming Test1,5,12,17,22,27, RBANS Language8, 13, Reading Subtest (WRAT-R)1,17, Vocabulary (WAIS, WASI)1,2,12,17,
Similarities (WAIS-R, WASI) 2,17,25
Visuospatial Block design (WAIS, WASI),1,2,4,5,12,17,22,25 design organization test,16 matrix reasoning (WAIS, WASI),2,17,24 novel image/novel
location,2 RBANS visual construction,8,13 and Rey complex figure test (copy)4,12, 17,18,23, 27
Motor function California computerized assessment package simple reaction time,4 choice reaction time,4 Fepsy finger tapping
test,1,7,10,18,20,23 and Perdue Grooved Peg Board2,5,9,8,13,16,22,24,25
aColumns includes neuropsychological measures and studies that employed the measure where: 1, Ahles et al. (12); 2, Ayala-Feliciano et al. (31); 3, Bender et al. (38);
4, Castellon et al. (32); 5, Collins et al. (33); 6, Collins et al. (34); 7, de Ruiter et al. (20); 8, Debess et al. (37); 9, Deprez et al. (21); 10, Donovan et al. (24); 11, Hermelink
et al. (25); 12, Hurria et al. (46); 13, Jansen et al. (35); 14, Jenkins et al. (43); 15, Jim et al. (36); 16, Koppelmans et al. (7); 17, Nguyen et al. (8); 18, Schagen et al. (22);
19, Scherwath et al. (26); 20, Schilder et al. (23); 21, Shilling et al. (19); 22, Stewart et al. (18); 23, van Dam et al. (5); 24, Vearncombe et al. (17); 25, Wefel et al. (27);
26, Wefel et al. (47); 27, Yamada et al. (9).
4. Calculation of 95% confidence intervals (CIs) surrounding
the two classes of weighted mean effect sizes (i.e., study and
cognitive domain); and
5. Calculation of Q and I 2 statistics to assess heterogeneity of
weighted mean effect sizes by cognitive domain and study
weighted mean effect sizes.
Cohen’s d (48) standardized mean difference effect sizes
using pooled SDs and corrected for small sample bias (i.e.,
Hedge’s g ) were used to determine the magnitude of difference
in performance of neuropsychological measures. Zakzanis (28)
proposed that Cohen’s d is the most appropriate measure for
neuropsychological research primarily due to its ability to explic-
itly account for the variability observed between neuropsychologi-
cal patients. Poorer cognitive functioning by chemotherapy groups
was represented by negative effect sizes. Cohen (48) defines a small
effect size as d≥ 0.2, a moderate effect as d ≥ 0.5, and a large effect
as d ≥ 0.8. Zakzanis (28) proposed that a Cohen’s d of >0.30 is an
appropriate marker of clinical significance in neuropsychological
functioning. All Cohen’s d statistics are expressed in SD units.
Both fixed and random effect models for combined sum-
mary effect sizes were computed. For fixed effect models, it is
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assumed that the true effect size is constant across all stud-
ies (e.g., cognitive impairment constant regardless of partici-
pant characteristics or cognitive domain), with variation being
due to sampling error. For random effect models, it is assumed
that the true effect size varies across studies due to known
and unknown factors (e.g., participant characteristics, cognitive
domain assessed).
Individual effect sizes were first calculated for every neuropsy-
chological measure used by a study. For cross-sectional studies
reporting means and SDs for neuropsychological test scores, d
(Eq. 1) was calculated by subtracting the chemotherapy group
mean score (X 1) from the comparison group mean score (X 2)
and dividing the result by the pooled SD (Spooled) (Eq. 2). N 1 is
the number of participants in the chemotherapy group, N 2 is the
number of participants in the comparison group, SD1 is the SD of
the mean score for the chemotherapy group, and SD2 is the SD of
the mean score for the control group:
d = (X2 − X1)
Spooled
(1)
where
Spooled =
√
(N1 − 1)SD21 + (N2 − 1)SD22
(N1 − 1)+ (N2 − 1) (2)
Similarly, for prospective longitudinal studies reporting means
and SDs for neuropsychological scores, d was calculated using
Eqs 1 and 2, subtracting the post-chemotherapy mean score
(X 2) from the pre-chemotherapy mean score (X 1) and divid-
ing the result by the pooled SD. N 1 is the number of partici-
pants pre-chemotherapy, N 2 is the number of participants post-
chemotherapy, SD1 is the SD of the mean score pre-chemotherapy,
and SD2 is the SD of the mean score post-chemotherapy.
All computed effect sizes were corrected for small sample bias
(Hedges g ) using the formula provided by Hedges (49) and dis-
played in Eq. 3. N is the total number of participants and d’ is the
unbiased standardized mean difference:
d ′ = d
[
1− 3
4N − 9
]
(3)
The variance for each individual effect size (vd) was calculated
using Eq. 4, with N being the sample size for each group in cross-
sectional studies and N being the sample size at each assessment
point in prospective longitudinal studies:
vd =
[
N1 + N2
N1N2
+ (d
′)2
2(N1 + N2)
]
(4)
The inverse of the sampling variance (Eq. 5) was used to weight
each effect size for the fixed effect model of analysis, while the
inverse of the sampling variance plus a random effects variance
constant (τθ) was used to weight each effect size for the random
effect model of analysis (Eq. 6):
wi = 1
vi
(5)
wi = 1
vi + τθ (6)
where
τθ = QT − (k − 1)∑
wi −
(∑
w2i∑
wi
) (7)
After calculation of individual effect sizes, two classes of
weighted mean effect sizes (d¯)were calculated (steps 2 and 3 of
the effect size protocol) for (1) studies and (2) cognitive domain.
A mean effect size was calculated for each study by averaging all
effect sizes and inverse variance weights within the study. There-
fore, each study produced an average effect size and an average
inverse variance weight. An average inverse variance weight was
used for studies, as weights are a function of sample size and
highly similar across effect sizes within a study. Weighted mean
effect sizes for cognitive domain were calculated from the individ-
ual effect sizes using the formula provided by Hedges and Olkin
(44). In Eq. 8, k is the number of effect sizes, w i= 1/vi (inverse
variance weight), and v i is the variance of the individual effect
size:
d =
[∑k
i−1 widi∑k
i−1 wi
]
(8)
The variance of the weighted mean effect size was then calcu-
lated using Eq. 9, which was then used to calculate 95% CIs for
weighted mean effect sizes to aid in the determination of statistical
significance (Eq. 10):
vd =
[
1∑k
i−1 wi
]
(9)
95% CI = d ± 1.96√vd (10)
Tests of the homogeneity of the two classes of weighted mean
effect sizes were performed to determine whether the effect sizes
were assessing common parameters. When the variation of effect
sizes is greater than that would be expected from sampling error
alone, the distribution of effect sizes is deemed to be heteroge-
neous and not representative of a common parameter (45). The
Q-statistic was calculated as a homogeneity test (Eq. 11):
Q =
k∑
i=1
wi(di − d)2 (11)
where k is the number of effect sizes, wi is the inverse variance
weight of each individual effect size, di is the individual effect size,
and d is the weighted mean effect size. If the Q-statistic exceeds a
critical value associated with a pre-determined alpha level (in the
present study, p< 0.05) the sample of effect sizes is characterized
as heterogeneous.
A number of variables were examined that may potentially
moderate the association between chemotherapy and cognitive
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impairment using meta-analytic regression, including time since
last chemotherapy treatment, type of control group, intelligence,
and patients’ average age at chemotherapy treatment. Weighted
mean study effect sizes were used for all moderator analyses, which
were performed separately for cross-sectional and prospective lon-
gitudinal studies. All moderators were examined as between-study
variables impacting on effect size magnitude and performed sep-
arately for cross-sectional and prospective longitudinal studies.
Finally, Duval and Tweedie’s (50) trim-and-fill method was used
to explore publication bias.
RESULTS
PARTICIPANTS
The 27 included studies comprised a total of 1562 breast can-
cer patients who received chemotherapy and 2799 comparison
individuals. The mean age of the chemotherapy and comparison
sample was 53.24 years (SD= 8.05) and 55.28 years (SD= 9.37),
respectively. For the 16 studies reporting education as a continuous
outcome, the mean years of education for the chemotherapy and
comparison sample was 14.16 (SD= 1.18) and 14.37 (SD= 1.46),
respectively. Previous studies typically reported that participants’
age and education level were matched between groups. For the
19 studies reporting data on intelligence, the mean IQ for the
chemotherapy and comparison sample was 108.79 (SD= 4.46)
and 108.13 (SD= 5.79), respectively. There was no signifi-
cant difference in mean IQ scores between chemotherapy and
comparison groups using a paired-samples t -test, t (14)= 0.42,
p> 0.05.
MEAN STUDY EFFECT SIZES
A total of 737 individual effect sizes for neuropsychological mea-
sures were calculated across all studies, with these effect sizes used
to calculate a weighted mean effect size for each study and cog-
nitive domain. Calculated effect sizes for each neuropsychological
measure are available on request.
CROSS-SECTIONAL STUDIES
Weighted mean effect sizes for cross-sectional studies using fixed
and random effect models are shown in Table 3. Mean effect
sizes ranged from −1.22 to 0.62 using the more conservative
random effect model, with 11 comparisons from eight studies
producing positive mean effect sizes (i.e., chemotherapy patients
exhibited better overall cognitive functioning in contrast to com-
parison groups). Of these, six comparisons showed a significant
positive effect size, and they compared cognitive functioning
between breast cancer patients with and without chemotherapy
(e.g., chemotherapy vs. local therapy).
Nevertheless, overall, in cross-sectional studies, patients treated
with chemotherapy exhibited significantly worse cognitive func-
tioning when contrasted with comparison groups, as shown in a
small but significant grand weighted mean effect size of d =−0.12
(95% CIs from −0.14 to −0.11) using a fixed effects model, and
d =−0.14 (95% CIs from−0.18 to−0.09) using a random effects
model. However, tests of homogeneity were statistically signifi-
cant for fixed effect (QTotal= 2519.48,p< 0.05) and random effect
(QTotal= 857.64, p< 0.05) grand weighted mean effect size mod-
els, indicating that the sampled effect sizes were not derived from
a single population.
PROSPECTIVE LONGITUDINAL STUDIES
Weighted mean effect sizes for prospective longitudinal studies
using fixed and random effect models are displayed in Table 4.
Mean effect sizes ranged from −0.29 to 1.12 using the more con-
servative random effect model, with only two comparisons pro-
ducing negative effect sizes representing worse cognitive function-
ing at follow-up compared to baseline assessments (34, 35). For
prospective longitudinal studies, chemotherapy patients exhib-
ited improved cognitive functioning from baseline (prior to
chemotherapy) to follow-up (after chemotherapy) assessments,
as shown in a small but significant grand weighted mean effect
size of d = 0.11 (95% CIs from 0.09 to 0.14) using a fixed effects
model, and d = 0.16 (95% CIs from 0.09 to 0.22) using a random
effects model. However, tests of homogeneity were statistically sig-
nificant for fixed effect (QTotal= 1212.07, p< 0.05) and random
effect (QTotal= 615.63, p< 0.05) grand weighted mean effect size
models, indicating that the sample of effect sizes were not derived
from a single population. It is likely that the direction (i.e., bet-
ter or worse cognitive functioning) and magnitude of effect sizes
was partly dependent on the length of follow-up time (e.g., short
vs. long follow-up), which is examined in subsequent moderator
analyses.
For both cross-sectional and prospective longitudinal studies,
there was significant variation within and across studies in the
magnitude of effect sizes produced. This may suggest that other
factors were impacting on the nature and magnitude of effect sizes
within and across studies (e.g., type of neuropsychological mea-
sure, time since chemotherapy), with this being the focus of the
remaining analyses.
COGNITIVE DOMAIN
Effect sizes were grouped according to cognitive domain (i.e.,
attention, executive function, language, long-term memory, motor
function, processing speed, short-term memory, and visuospatial
function) for cross-sectional and prospective longitudinal stud-
ies using both fixed and random effect models (Table 5). There
was variation in the magnitude of weighted mean effect sizes
across cognitive domains, indicating that receiving chemotherapy
was likely to be associated with specific rather than generalized
cognitive effects.
For cross-sectional studies, weighted mean effect sizes ranged
from −0.04 to −0.25 for cognitive domains using the more con-
servative random effects model. The largest effect sizes using
the random effects model were found for the processing speed
(d =−0.25) and executive function (d =−0.19) domains, indi-
cating that when aggregating data across all studies, chemotherapy
patients were more likely to experience impairments in these two
domains relative to comparison groups. Weighted mean effect
sizes for the cognitive domains of language, long-term mem-
ory and visuospatial function were not significantly different
from zero using the random effects model, indicating that on
average chemotherapy patients did not experience consistently
marked impairments in these domains in contrast to compar-
ison groups. Tests of homogeneity were statistically significant
for fixed effect (QTotal= 80.98, p< 0.05), but not for random
effect (QTotal= 28.02, p> 0.05) cognitive domain weighted mean
effect size models. This provides some evidence that variation
Frontiers in Oncology | Neuro-Oncology March 2015 | Volume 5 | Article 59 | 8
                                                         
O
no
et
al.
M
eta-analysis
of
cognition
in
breast
cancer
Table 3 | Weighted mean effect sizes for cross-sectional studies.
Study: authors, reference, comparison
group
k Fixed effect model Random effect model
Effect
size (SE)
95% CI z Q Effect
size (SE)
95% CI z Q
Grand mean weighted effect size 509 −0.12 (0.01)* −0.14 to −0.10 −13.40 2519.48* −0.14 (0.02)* −0.18 to −0.09 −6.38 857.54*
Ahles et al. (12), local therapy only 24 −0.16 (0.05)* −0.25 to −0.07 −3.31 18.67 −0.16 (0.10) −0.35 to 0.03 −1.69 4.79
Ayala-Feliciano et al. (31), healthy comparison 10 −1.12 (0.11)* −1.34 to −0.90 −10.01 85.92* −1.22 (0.17)* −1.55 to −0.89 −7.29 39.97*
Bender et al. (38), chemotherapy only vs.
patients without tamoxifen and
chemotherapy, 1 week follow-up
7 0.56 (0.17)* 0.23 to 0.88 3.33 66.68* 0.62 (0.22)* 0.19 to 1.06 2.80 41.11*
Bender et al. (38), chemotherapy and
tamoxifen vs. patients without tamoxifen and
chemotherapy, 1 week follow-up
7 0.32 (0.17) −0.02 to 0.65 1.87 47.28* 0.35 (0.22) −0.09 to 0.79 1.57 29.17*
Bender et al. (38), chemotherapy only vs.
patients without tamoxifen and
chemotherapy, 1 year follow-up
7 −0.42 (0.24) −0.89 to 0.06 −1.73 70.43 −0.58 (0.29)* −1.14 to −0.01 −2.01 56.54*
Bender et al. (38), chemotherapy and
tamoxifen vs. patients without tamoxifen and
chemotherapy, 1 year follow-up
7 −0.63 (0.28)* −1.18 to −0.08 −2.26 94.89* −0.68 (0.32)* −1.30 to −0.05 −2.13 75.95
Castellon et al. (32), local therapy only 20 −0.39 (0.07)* −0.51 to −0.26 −5.95 19.08 −0.39 (0.11)* −0.61 to −0.17 −3.53 6.62
Castellon et al. (32), healthy comparison 20 −0.23 (0.06)* −0.35 to −0.11 −3.71 19.44 −0.23 (0.11)* −0.45 to −0.02 −2.15 6.43
Collins et al. (33), hormonal therapy only, one
month follow-up
22 0.11 (0.04)* 0.02 to 0.20 2.51 18.29 0.11 (0.10) −0.08 to 0.30 1.15 3.84
Collins et al. (33), hormonal therapy only, one
year follow-up
22 0.01 (0.04) −0.07 to 0.10 0.33 23.15 0.02 (0.10) −0.17 to 0.20 0.17 4.97
Collins et al. (34), healthy comparison 12 −0.33 (0.06)* −0.44 to −0.21 −5.57 14.53 −0.33 (0.13)* −0.58 to −0.08 −2.58 3.09
de Ruiter et al. (20), without chemotherapy 15 −0.21 (0.09)* −0.38 to −0.04 −2.40 6.43 −0.21 (0.13) −0.47 to 0.05 −1.56 2.70
Debess et al. (37), local therapy only 4 0.13 (0.12) −0.10 to 0.35 1.10 4.51 0.13 (0.22) −0.30 to 0.55 0.59 1.28
Debess et al. (37), healthy comparison 4 −0.09 (0.06) −0.20 to 0.03 −1.42 2.92 −0.09 (0.19) −0.46 to 0.29 −0.45 0.29
Deprez et al. (21), healthy comparison 4 −0.83 (0.17)* −1.17 to −0.49 −4.77 0.52 −0.83 (0.25)* −1.32 to −0.33 −3.29 0.25
Donovan et al. (24), local therapy only 11 0.08 (0.05) −0.01 to 0.18 1.66 7.94 0.08 (0.13) −0.17 to 0.33 0.64 1.17
Jenkins et al. (43), healthy comparison, four
weeks follow-up
13 −0.13 (0.05)* −0.22 to −0.03 −2.63 6.68 −0.13 (0.12) −0.36 to 0.11 −1.06 1.08
Jenkins et al. (43), local therapy only, four
weeks follow-up
13 0.11 (0.05)* 0.01 to 0.21 2.19 6.26 0.11 (0.12) −0.13 to 0.35 0.91 1.08
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Table 3 | Continued
Study: authors, reference, comparison
group
k Fixed effect model Random effect model
Effect
size (SE)
95% CI z Q Effect
size (SE)
95% CI z Q
Jenkins et al. (43), healthy comparison, one
year follow-up
13 −0.13 (0.05)* −0.22 to −0.03 −2.66 19.20 −0.13 (0.12) −0.36 to 0.11 −1.06 3.17
Jenkins et al. (43), local therapy only, one
year follow-up
13 0.15 (0.05)* 0.05 to 0.25 3.03 9.08 0.15 (0.12) −0.08 to 0.39 1.27 1.58
Jim et al. (36), healthy comparison 13 −0.75 (0.05)* −0.83 to −0.66 −16.45 1071.00* −0.74 (0.12)* −0.98 to −0.50 −6.15 326.39*
Koppelmans et al. (7), healthy comparison 15 −0.11 (0.02)* −0.15 to −0.07 −5.62 20.22 −0.11 (0.10) −0.31 to 0.10 −1.03 0.69
Nguyen et al. (8), local therapy only 21 0.23 (0.06)* 0.11 to 0.34 3.93 51.14* 0.24 (0.10)* 0.03 to 0.44 2.26 16.62
Nguyen et al. (8), healthy comparison 21 −0.18 (0.06)* −0.29 to −0.07 −3.07 64.00* −0.19 (0.10) −0.39 to 0.02 −1.78 19.87
Schagen et al. (22), local therapy only 20 −0.28 (0.05)* −0.38 to −0.18 −5.41 17.48 −0.28 (0.10)* −0.48 to −0.08 −2.72 4.37
Scherwath et al. (26), high-dose
chemotherapy vs. without chemotherapy
15 −0.03 (0.07) −0.17 to 0.10 −0.47 12.37 −0.03 (0.12) −0.28 to 0.21 −0.27 3.91
Scherwath et al. (26), standard-dose
chemotherapy vs. without chemotherapy
15 −0.04 (0.07) −0.18 to 0.09 −0.62 6.05 −0.04 (0.12) −0.29 to 0.20 −0.35 1.93
Schilder et al. (23), healthy comparison 17 −0.27 (0.04)* −0.36 to −019 −6.25 24.20 −0.27 (0.11)* −0.48 to −0.07 −2.59 4.11
Shilling et al. (19), healthy comparison 8 −0.22 (0.07)* −0.36 to −0.09 −3.20 12.57 −0.22 (0.15) −0.52 to 0.08 −1.46 2.61
Stewart et al. (18), hormonal therapy 22 0.04 (0.04) −0.04 to 0.11 0.90 18.91 0.04 (0.09) −0.15 to 0.22 0.39 3.41
van Dam et al. (5), high-dose chemotherapy
vs. without chemotherapy
18 −0.27 (0.06)* −0.38 to −0.16 −4.80 47.20* −0.27 (0.11)* −0.49 to −0.06 −2.48 12.75
van Dam et al. (5), standard-dose
chemotherapy vs. without chemotherapy
18 −0.16 (0.06)* −0.27 to −0.06 −2.99 20.27 −0.17 (0.11) −0.38 to 0.05 −1.52 5.24
Vearncombe et al. (17), without
chemotherapy
13 0.13 (0.06)* 0.01 to 0.26 2.15 9.61 0.14 (0.13) −0.11 to 0.38 1.07 2.38
Yamada et al. (9), healthy comparison 12 −0.39 (0.07)* −0.54 to −0.25 −5.40 26.54* −0.40 (0.13)* −0.67 to −0.14 −2.98 7.85
Q total 2519.48* Q total 857.64*
(df=509) (df=509)
Q within 1943.48* Q within 697.21*
(df=475) (df=475)
Q between 576.00* Q between 160.43*
(df=33) (df=33)
*p<0.05.
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Table 4 | Weighted mean effect sizes for prospective longitudinal studies.
Study: Authors, reference, timing
of follow-up
k Fixed effect model Random effect model
Effect size (SE) 95% CI z Q Effect size (SE) 95% CI z Q
Grand mean weighted effect size 228 0.11 (0.01)* 0.09 to 0.14 8.78 1212.07* 0.16 (0.03)* 0.09 to 0.22 5.03 615.63*
Bender et al. (38), 1 week follow-up 18 1.02 (0.10)* 0.82 to 1.22 10.01 141.21* 1.12 (0.14)* 0.83 to 1.40 7.73 77.50*
Bender et al. (38),1 year follow-up 16 0.55 (0.13)* 0.30 to 0.79 4.36 266.88* 0.70 (0.16)* 0.38 to 1.03 4.30 181.48*
Collins et al. (33),1 year follow-up 23 0.21 (0.04)* 0.13 to 0.29 5.08 13.69* 0.21 (0.09)* 0.03 to 0.39 2.24 2.64
Collins et al. (33),1 month follow-up 23 0.10 (0.04)* 0.02 to 0.18 2.36 12.07 0.10 (0.09) −0.09 to 0.28 1.03 2.31
Collins et al. (34), During
chemotherapy
13 −0.22 (0.06)* −0.34 to −0.10 −3.58 191.60* −0.26 (0.13)* −0.51 to −0.00 −1.98 182.66*
Debess et al. (37), 4 weeks
follow-up
5 0.20 (0.07)* 0.06 to 0.34 2.75 2.94 0.20 (0.19) −0.18 to 0.58 1.03 0.42
Hermelink et al. (25), between last
second and last chemotherapy
12 0.20 (0.04)* 0.12 to 0.28 5.05 19.90 0.20 (0.12) −0.04 to 0.45 1.67 2.15
Hurria et al. (16),6 months follow-up 13 0.05 (0.08) −0.10 to.0.20 0.68 8.71 0.05 (0.14) −0.21 to 0.32 0.40 2.79
Jansen et al. (35),6 months
follow-up
7 −0.08 (0.07) −0.22 to 0.05 −1.19 254.66* −0.29 (0.17) −0.62 to 0.04 −1.71 64.30*
Jenkins et al. (43),18 months
follow-up
14 0.08 (0.04) −0.00 to 0.16 1.95 19.79 0.08 (0.11) −0.14 to 0.31 0.70 2.54
Jenkins et al. (43),4 weeks follow-up 14 0.03 (0.04) −0.05 to 0.11 0.80 11.65 0.03 (0.11) −0.19 to 0.26 0.29 1.49
Shilling et al. (19),6 months
follow-up
9 0.05 (0.07) −0.08 to 0.18 0.73 15.89 0.05 (0.15) −0.24 to 0.34 0.33 3.19
Stewart et al. (18),2 months
follow-up
23 0.12 (0.04)* 0.04 to 0.19 3.03 13.50 0.12 (0.09) −0.06 to 0.30 1.28 2.37
Vearncombe et al. (17), 4 weeks
follow-up
14 0.06 (0.03)* 0.00 to 0.13 1.98 66.04* 0.06 (0.11) −0.16 to 0.28 0.57 5.67
Wefel et al. (27), 3 weeks follow-up 10 0.18 (0.11) −0.03 to 0.38 1.67 2.47 0.18 (0.17) −0.15 to 0.50 1.07 1.01
Wefel et al. (27), 1 year follow-up 10 0.26 (0.11)* 0.04 to 0.48 2.33 3.20 0.26 (0.17) −0.07 to 0.59 1.55 1.41
Wefel et al. (27), 1 year follow-up 6 0.22 (0.10)* 0.02 to 0.42 2.16 15.66* 0.22 (0.19) −0.16 to 0.60 1.14 4.33
Q total (df=228) 1212.07* Q total (df=228) 615.63*
Q within (df=211) 1059.84* Q within (df=211) 538.24*
Q between (df=16) 152.22* Q between (df=16) 77.39*
*p<0.05.
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Table 5 | Weighted mean effect sizes for cognitive domain.
Cognitive domain k Fixed effect model Random effect model
Effect size (SE) 95% CI z Q Effect size (SE) 95% CI z Q
Cross-sectional studies
Attention 107 −0.13 (0.02)* −0.18 to −0.09 −6.22 313.21* −0.16 (0.05)* −0.25 to −0.07 −3.49 74.93
Executive function 83 −0.16 (0.02)* −0.21 to −0.12 −7.45 324.25* −0.19 (0.05)* −0.30 to −0.09 −3.72 62.57
Language 17 −0.04 (0.06) −0.16 to 0.08 −0.60 42.25* −0.08 (0.12) −0.31 to 0.16 −0.64 14.68
Long-term memory 121 −0.08 (0.02)* −0.12 to −0.04 −4.10 766.84* −0.04 (0.04) −0.13 to 0.05 −0.88 296.99*
Motor function 34 −0.11 (0.03)* −0.17 to −0.05 −3.45 147.77* −0.16 (0.08)* −0.32 to −0.00 −1.98 55.54*
Processing speed 32 −0.23 (0.03)* −0.29 to −0.16 −7.10 116.46* −0.25 (0.08)* −0.41 to −0.09 −3.04 19.41
Short-term memory 93 −0.11 (0.02)* −0.15 to −0.07 −5.64 701.65* −0.15 (0.05)* −0.25 to −0.05 −3.04 296.20*
Visuospatial function 22 −0.02 (0.05) −0.11 to 0.07 −0.48 80.98* −0.06 (0.10) −0.26 to 0.14 −0.55 28.02
Q total (df=509) 2519.48* Q total (df=509) 857.64*
Q within (df=501) 2493.41* Q within (df=501) 848.35*
Q between (df=7) 26.08* Q between (df=7) 9.29
Prospective longitudinal studies
Attention 52 0.12* (0.02) 0.07 to 0.17 4.88 60.53 0.12 (0.06) −0.00 to 0.24 1.93 11.98
Executive function 37 0.08* (0.03) 0.02 to 0.13 2.56 58.83* 0.08 (0.07) −0.06 to 0.28 1.11 10.17
Language 8 0.31* (0.08) 0.16 to 0.47 3.91 15.69* 0.26 (0.17) −0.07 to 0.59 1.57 2.92
Long-term memory 55 0.22* (0.03) 0.17 to 0.28 8.29 333.63* 0.41* (0.06) 0.28 to 0.54 6.38 162.97*
Motor function 9 −0.10 (0.07) −0.23 to 0.04 −1.44 33.68* −0.00 (0.16) −0.37 to 0.24 −0.41 6.38
Processing speed 7 0.14* (0.07) 0.01 to 0.28 2.12 7.19 0.12 (0.17) −0.21 to 0.45 0.73 1.37
Short-term memory 51 0.06* (0.03) 0.01 to 0.12 2.22 482.73* 0.08 (0.07) −0.05 to 0.22 1.24 340.84*
Visuospatial function 9 −0.18* (0.07) −0.31 to −0.04 −2.53 164.60* −0.29 (0.16) −0.60 to 0.18 −1.85 50.41*
Q total (df=228) 1212.07* Q total (df=228) 615.63*
Q within (df=220) 1156.89* Q within (df=220) 587.04*
Q Between (df=7) 55.18* Q between (df=7) 28.59*
*p<0.05.
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in effect sizes was reduced when taking cognitive domain into
consideration for cross-sectional studies.
For prospective longitudinal studies, weighted mean effect sizes
ranged from −0.29 to 0.41 for cognitive domains using the more
conservative random effects model. Long-term memory was the
only cognitive domain to produce a significant mean effect size
(d = 0.41), indicating that chemotherapy patients typically exhib-
ited improvements in long-term memory when re-assessed after
baseline and after chemotherapy treatment had been completed.
Tests of homogeneity were statistically significant for fixed effect
(QTotal= 1212.07, p< 0.05), and random effect (QTotal= 615.63,
p< 0.05) cognitive domain weighted mean effect size models. This
indicated that variation in effect sizes remained even after taking
cognitive domain into consideration for prospective longitudinal
studies.
Figure 2 displays forest plots of weighted mean effect sizes for
cognitive domains for cross-sectional and prospective longitudi-
nal studies, where the mean effect size is represented by the marker,
and the upper and lower 95% CIs for the estimate are represented
by the horizontal lines connected to the marker. As shown in
Figure 2, cross-sectional studies found a negative weighted mean
effect size for all cognitive domains with a significant negative
effect in five domains. On the other hand, prospective longitudinal
studies found positive weighted mean effect sizes for most (6/8)
cognitive domains with only one domain showing a significant
positive mean effect size.
MODERATORS
Meta-analytic regression was performed separately for cross-
sectional and prospective longitudinal studies reporting data for
the potential moderators of time since last chemotherapy treat-
ment, average age when receiving chemotherapy, and comparison
group type (healthy vs. patient controls) for cross-sectional studies
only. For these analyses, mean study effect sizes were the depen-
dent variable, and the inverse variance of mean effect sizes was
used as the weighting variable. Displayed in Table 6 is a summary
of the meta-analytic regression analyses for moderators using a
random effects model.
For cross-sectional studies, the Qmodel was significant
(Qmodel= 24.63, df= 4, p< 0.001; QResidual= 89.49, df= 15,
p< 0.001), indicating that the moderator variables together
accounted for a significant level of variability in effect sizes. The
variables of comparison group and average years of education were
significant moderators of mean study effect sizes. These results
indicated that poorer performance on neuropsychological tests
by chemotherapy patients (i.e., negative effect sizes) was associ-
ated with studies using healthy comparison groups (vs. patient
comparisons), and chemotherapy patients with fewer years of
education.
For prospective longitudinal studies, the Qmodel was not sig-
nificant (Qmodel= 6.76, df= 3, p> 0.05; QResidual= 83.96, df= 8,
p< 0.001), indicating that the moderator variables together did
not account for a significant level of variability in effect sizes.
Cross−Sectional Studies
−0.60 −0.40 −0.20 0.00 0.20
Weighted Mean Effect Size (Random Effects Model)
Visuospatial Function
Short Term Memory
Processing Speed
Motor Function
Long Term Memory
Language
Executive Function
Attention
−0.06 [ −0.26 ,  0.14 ]
−0.15 [ −0.25 , −0.05 ]
−0.25 [ −0.41 , −0.09 ]
−0.16 [ −0.32 ,  0.00 ]
−0.04 [ −0.13 ,  0.05 ]
−0.08 [ −0.31 ,  0.16 ]
−0.19 [ −0.29 , −0.09 ]
−0.16 [ −0.25 , −0.07 ]
Cognitive Domain Observed [95% CI]
Prospective Studies
−1.00 −0.50 0.00 0.50 1.00
Weighted Mean Effect Size (Random Effects Model)
Visuospatial Function
Short Term Memory
Processing Speed
Motor Function
Long Term Memory
Language
Executive Function
Attention
−0.29 [ −0.60 , 0.02 ]
 0.08 [ −0.05 , 0.22 ]
 0.12 [ −0.21 , 0.45 ]
−0.06 [ −0.37 , 0.24 ]
 0.41 [  0.28 , 0.54 ]
 0.26 [ −0.07 , 0.59 ]
 0.08 [ −0.06 , 0.23 ]
 0.12 [  0.00 , 0.24 ]
Cognitive Domain Observed [95% CI]
FIGURE 2 | Forest plot of cognitive domain weighted mean effect sizes for cross-sectional and prospective longitudinal studies.
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Table 6 | Meta-analytic regression results for moderator variables.
Variable B SE z 95% CI
Cross-sectional studies
Intercept 0.75 0.90 0.83 −1.03 to 2.51
Comparison group −0.52*** 0.13 −4.02 −0.78 to −0.27
Age at treatment 0.02 0.01 1.82 −0.00 to 0.04
Time since final
chemotherapy treatment
−0.00 0.00 −1.07 −0.00 to 0.00
Average years of education −0.12* 0.05 −2.19 −0.22 to −0.01
R2=0.60
QModel=24.63*** (df=4)
QResidual=89.49***
(df=15)
Prospective longitudinal
studies
Intercept 1.25 1.05 1.19 −0.81 to 3.30
Age at treatment −0.03** 0.01 −2.58 −0.06 to −0.01
Average years of education 0.04 0.07 0.59 −0.09 to 0.17
Time since final
chemotherapy treatment
−0.00 0.00 −0.13 −0.00 to 0.00
R2=0.26
QModel=6.76 (df=3)
QResidual=83.96***
(df=8)
*p<0.05.
**p<0.01.
***p<0.001.
However, the variable of age at treatment emerged as a significant
moderator, indicating that older age at chemotherapy treatment
was associated with poorer performance on neuropsychological
measures at follow-up.
For cross-sectional studies, effect sizes were calculated for IQ
differences between chemotherapy and comparison groups for
studies reporting such data, with negative effect sizes representing
poorer intellectual functioning in chemotherapy groups. Study
effect sizes (fixed effect model) ranged from -0.73 to 0.69, with
the average weighted effect size for group differences in IQ being
d = -0.02 (95% CIs from -0.10 to 0.07) across studies, indicating
no significant difference between chemotherapy and comparison
groups in IQ. Using meta-analytic regression (fixed effect model),
mean IQ effect sizes were not significantly associated with mean
study effect sizes for neuropsychological measures (QModel= 1.47,
df= 1, p> 0.05; QResidual= 491.16, df= 23, p< 0.001).
There were only six prospective longitudinal studies report-
ing data on IQ. Given this small sample size, no analyses were
conducted to examine the association between IQ and effect size
magnitude for prospective longitudinal studies.
PUBLICATION BIAS
The trim-and-fill method (50) was used to assess publication bias
separately for cross-sectional and prospective longitudinal studies
using random effect model estimates. Inspection of the observed
funnel plots of mean study effect sizes and the standard error of
effect sizes in Figure 3 indicated symmetry around the overall
weighted mean effect size suggestive of no significant publication
bias for both cross-sectional and prospective longitudinal studies.
Trim-and-fill analyses confirmed that no additional studies were
required to adjust for an asymmetrical distribution of effect sizes
for cross-sectional and prospective longitudinal studies.
DISCUSSION
In the current meta-analysis, 27 studies (N = 4361 participants)
were reviewed and 737 effect sizes were generated to address two
study aims: to examine the magnitude of cognitive impairment
in eight cognitive domains and to identify factors moderating the
magnitude of post-chemotherapy cognitive impairment among
breast cancer patients. The findings generally indicated that the
magnitude of cognitive impairment among chemotherapy groups
varied within and across studies. Regardless, the grand mean
weighted effect size suggests that subtle cognitive impairment
was associated with adjuvant chemotherapy among breast can-
cer patients. This is consistent with previous meta-analyses (10,
11, 14, 15). The small but significant grand mean effect size may
be due, partly, to varying levels of impairment across different
cognitive domains and moderating factors not being taken into
account. The mean effect sizes are discussed separately for each
study design (cross-sectional vs. prospective).
STUDY MEAN EFFECT SIZES BY STUDY DESIGN
Cross-sectional studies
Overall, breast cancer patients with a history of chemotherapy
performed slightly, but significantly worse than their comparison
groups. Nevertheless, 6 out of 34 comparisons from cross-sectional
studies indicated that breast cancer patients previously treated
with chemotherapy performed significantly better than individ-
uals in the control group. However, these results were all based
on comparisons of cognitive functioning between breast cancer
patients with and without chemotherapy. Thus, these comparisons
suggest that, generally, breast cancer patients previously treated
with chemotherapy exhibit cognitive impairment as compared to
their counterparts, but their impairment may not be worse than
some breast cancer patients without chemotherapy.
Prospective longitudinal studies
In contrast, the grand mean effect size from the prospective longi-
tudinal studies suggested that cognitive functioning among breast
cancer patients treated with chemotherapy is slightly, but statisti-
cally significantly better after chemotherapy. However, this may
not necessarily suggest that chemotherapy improves cognitive
functioning or refutes the negative effects of chemotherapy on
cognitive function. There are two other explanations, which are
related to time since treatment and methodological limitations.
First, the results may be due to the timing of post-treatment
assessment. It has been suggested that cognitive impairment asso-
ciated with chemotherapy among breast cancer patients improves
over time (10, 27, 43, 47). Follow-up assessment in these prospec-
tive longitudinal studies was conducted between 1–3 (33, 37, 38,
43) and/or 6–18 months (33, 35, 38, 43, 46) after last chemother-
apy. Cognitive impairment at longer term follow-up may not
be as marked as during or just after treatment. For example,
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FIGURE 3 |Trim-and-fill analysis observed funnel plots for publication bias in mean study effect size.
breast cancer patients may have recovered from short-term cogni-
tive impairment associated with chemotherapy and/or developed
compensatory cognitive strategies after experiencing a series of
chemotherapy doses. Given this possibility, time since treatment
was examined as a moderating factor and is discussed later. How-
ever, some breast cancer patients treated with chemotherapy show
long-term cognitive impairment (7), and a previous meta-analysis
(11) did not find time since treatment to be a moderating factor. In
addition, this does not explain why breast cancer patients’cognitive
functioning is better than (rather than equal to) pre-chemotherapy
levels. Thus, other explanations need to be explored.
An alternative explanation relates to methodological issues
inherent in prospective longitudinal studies. The first method-
ological issue that may have affected the results is potential
practice effects on patients’ performance at follow-up. How-
ever, most prospective longitudinal studies included a method
for managing practice effects. For example, a control group was
employed to correct for practice effects (17, 25, 34) and/or alter-
native forms of tests were used at follow-up (27, 35, 38). Other
studies employed a statistical correction for practice effects (18,
19, 27, 43). Regardless, practice effects were reported in stud-
ies that had employed alternative forms of tests at follow-up
(35, 38). Indeed, only one study (34) reported significant post-
chemotherapy cognitive decline among breast cancer patients.
Furthermore, improved post-chemotherapy cognitive function-
ing was reported even when a control group was included (17, 25).
These studies found improved post-chemotherapy cognitive func-
tioning, even after quantifying and adjusting for practice effects
based on improved performance in controls. Thus, practice effects
may not fully explain improved post-chemotherapy cognitive
function in patients.
The second methodological issue that may explain improved
post-chemotherapy cognitive function relates to the timing of
baseline assessment. More specifically, in all prospective longitudi-
nal studies, patients’ baseline cognitive functioning was measured
prior to chemotherapy, but either after diagnosis with and with-
out some treatment (19, 25, 27, 35, 46, 47) or even after surgery
(17, 18, 33, 34, 37, 38, 43). Consequently, the patients were aware
of the presence of breast cancer, and some underwent a surgery
or treatment, waiting for the commencement of chemotherapy.
All but three studies in the current meta-analysis (19, 25, 47)
either excluded breast cancer patients with psychiatric disorders,
reported no significant group differences in psychological factors
(fatigue, depression, and anxiety); or controlled for such factors.
However, it is possible that emotional factors associated with a
diagnosis of breast cancer (i.e., acute stress, depression) could
negatively influence cognitive functioning for some individuals.
Therefore, baseline data used in those studies may not be the
same as patients’ pre-diagnosis baseline cognitive functioning.
For instance, if chemotherapy patients’ post-diagnosis (i.e., pre-
chemotherapy) performance was significantly worse than their
pre-diagnosis baseline, their post-chemotherapy performance is
likely to be better than their pre-chemotherapy performance.
Then, even if their post-chemotherapy performance was much
better than their post-diagnosis/pre-chemotherapy baseline, this
may still be significantly worse than pre-diagnosis performance.
Indeed, some studies have noted impaired performance in women
with breast cancer prior to chemotherapy, in support of this
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explanation (25, 51). Therefore, the difference between pre- and
post-chemotherapy cognitive performance in those studies may
represent only a partial trajectory of post-chemotherapy cogni-
tive functioning among breast cancer patients. This may in part
explain improved post-chemotherapy cognitive function among
breast cancer patients.
COGNITIVE IMPAIRMENT BY COGNITIVE DOMAINS
Cross-sectional studies
It was found that breast cancer patients previously treated with
chemotherapy performed significantly worse than (healthy or can-
cer) controls in the domains of attention, executive function,
motor function, processing speed, and short-term memory. The
level of cognitive function among chemotherapy patients in the
domains of language, long-term memory, and visuospatial func-
tion was not significantly different from their counterparts. Of
the previous meta-analyses, only Falleti et al. (10) analyzed effect
sizes for cognitive domains by study design, and they found signif-
icant cognitive impairment in the domains of attention, executive
function, motor function, verbal ability, visuospatial ability, and
memory. Therefore, the current results are partially consistent
with Falleti et al. (10). The inconsistency may be partly due to
an increased number of comparisons included in the current
meta-analysis. It should be noted that the level of heterogeneity of
cross-sectional studies was non-significant using a random effect
model when studies were analyzed by cognitive domains. This
supports the validity of the current results and suggests that the
magnitude of post-chemotherapy cognitive impairment among
breast cancer patients varies, depending on the cognitive domain.
Prospective longitudinal studies
In contrast, no post-chemotherapy cognitive decline was found
among breast cancer patients in prospective longitudinal stud-
ies. Instead, breast cancer patients showed significantly improved
long-term memory after chemotherapy. Although Falleti et al. (10)
found post-chemotherapy cognitive improvement among breast
cancer patients, they included only one study. Thus, there is no
previous review to allow comparison with the current results.
In addition, as discussed previously, issues regarding the varied
timing of post-chemotherapy assessment, practice effects, and
post-diagnosis baseline need to be considered in the interpretation
of results from prospective longitudinal studies.
The cognitive domains (except visuospatial function) that
showed less impairment in cross-sectional studies were also those
more likely to show greater improvement in prospective longitu-
dinal studies. For example, long-term memory was found to be
least impaired in cross-sectional studies and was found to be the
domain most likely to improve in prospective longitudinal studies.
Although hypothetical, long-term memory may be the cognitive
domain that is less likely to be affected by chemotherapy and/or
is more likely to improve faster than other domains. Alternatively,
it is possible that measures of long-term memory may be more
susceptible to practice effects.
Language and visuospatial function have previously been
reported as the most impaired cognitive domains among breast
cancer patients treated with chemotherapy (10, 11, 14, 15). How-
ever, the magnitude of post-chemotherapy cognitive impairment
and cognitive decline in language and visuospatial function among
breast cancer patients was non-significant in this review. The dis-
crepancy in findings between previous meta-analyses and this
analysis may be due to an increased number of comparisons
included in this study. More specifically, the results in previous
meta-analyses were derived from a small number of comparisons
(k = 3–15 for language and k = 5-10 for visuospatial function).
Whereas in the present meta-analysis a larger number of com-
parisons was included, the domains were examined separately
for cross-sectional studies (k = 17 for language and k = 22 for
visuospatial function) and for prospective longitudinal studies
(k = 8 for language and k = 9 for visuospatial function). Based on
the large number of comparisons and separate analyses by study
design, these domains were found to be non-significant. It should
be noted that the CIs of the grand mean effect sizes for language
and visuospatial function varied widely, and the non-significant
results may be due to variability across studies in the results on
these domains.
EFFECTS OF MODERATORS
Cross-sectional studies
Among cross-sectional studies, type of control group was found
to significantly moderate the magnitude of cognitive impairment.
More specifically, level of cognitive functioning among breast can-
cer patients with a history of chemotherapy was significantly
worse than healthy controls, but not significantly worse than
breast cancer patients without chemotherapy. In addition, level
of education was found to significantly moderate the magnitude
of post-chemotherapy cognitive impairment. That is, chemother-
apy patients with lower levels of education tend to show greater
cognitive impairment than those with higher levels of education.
However, time since treatment and age at treatment were not sig-
nificant moderators. These results contrast with those of Falleti
et al. (10) but are partially consistent with Jim et al. (11) who found
non-significant moderating effects of time since treatment and
age. The meta-analysis by Falleti et al. (10) was based on only six
cross-sectional studies and did not include type of control group as
a moderator, which was found to be the most significant factor in
the current review. These differences may explain the inconsistent
findings. The main findings arising from the cross-sectional stud-
ies are that significantly greater cognitive impairment is observed
among breast cancer patients previously treated with chemother-
apy when compared to healthy controls, and that lower education
level may be a risk factor for cognitive impairment. However,
it is further noteworthy that levels of cognitive impairment are
similar among breast cancer patients, irrespective of a history of
chemotherapy.
Prospective longitudinal studies
Conversely, in prospective longitudinal studies older age was asso-
ciated with increased levels of cognitive decline among breast
cancer patients previously treated with chemotherapy. Falleti
et al. (10) found the opposite results, with younger breast cancer
patients exhibiting greater cognitive impairment after chemother-
apy. However, their results were based on cross-sectional studies
only and thus cannot be directly compared to the present findings.
The current review suggests that cognitive decline associated with
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chemotherapy for breast cancer may interact with age, whereby
older patients may have a higher risk of developing and/or experi-
encing persisting cognitive decline after chemotherapy. The nega-
tive effects of older age on cognitive function are well documented
(52), including cognitive decline in the domains of processing
speed, attention and executive function. Thus, it is possible that
chemotherapy exacerbates the effects of old age on cognitive
function for breast cancer patients.
STRENGTHS AND LIMITATIONS OF CURRENT REVIEW
The current meta-analysis extended upon previous reviews to
improve understanding of the effects of chemotherapy on cog-
nitive functioning among breast cancer patients. The results were
based on good search strategy and a larger number of studies
that employed validated neuropsychological measures. Indeed, the
results of the publication bias analysis supported the validity of
the findings. In addition, study design (e.g., cross-sectional vs.
prospective) has been suggested to moderate the results (10, 11). To
address this issue, the grand mean effect sizes and meta-regression
analyses of moderators were conducted for cross-sectional studies
and prospective longitudinal studies.
Regardless of these strengths, some limitations need to be
acknowledged, many of which are inherent in meta-analyses. First,
as suggested in Q statistics, the effect sizes varied significantly
across studies, and studies were heterogeneous with respect to
many factors, such as the measures used, participants’ characteris-
tics, cancer stages, type and dosage of chemotherapy and hormone
therapy, time since therapy, and control type. Therefore, whether
these factors moderate the results is yet to be examined. In addi-
tion, although the type of control group was found to significantly
moderate the magnitude of post-chemotherapy cognitive impair-
ment, other potential moderators, such as type and dosage of
chemotherapy and the current use of tamoxifen, were not included
in this review.
FUTURE DIRECTIONS
As discussed above, it is important to examine other factors that
potentially moderate the magnitude of post-chemotherapy cogni-
tive impairment/declining, especially over the long-term. First, it
is still uncertain whether the use of tamoxifen itself, or the interac-
tion between tamoxifen and chemotherapy, leads to the develop-
ment of and/or persistence of cognitive impairment among breast
cancer patients. This question is not new, yet the findings of pre-
vious meta-analyses have been mixed (10, 11). Second, it also
remains unclear whether or not level of cognitive performance
at pre-chemotherapy (but post-diagnosis) is the same as that at
pre-diagnosis. To answer these research questions, a prospective
longitudinal study needs to be conducted, in which cognitive
functioning is compared between four groups: healthy controls;
breast cancer patients with chemotherapy only (and no hormone
therapy); patients with chemotherapy and hormone therapy; and
patients with hormone therapy only. Cognitive functioning should
be measured prior to diagnosis (e.g., at regular screening exam-
inations), as well as just before, during, and after chemotherapy.
This type of study would also answer another research question
that emerged from this review – whether or not the effects of
chemotherapy on cognitive functioning are worse than those of
other treatments. However, this type of study may not be eas-
ily conducted, and conducting a cross-sectional study with an
improved study design would still be helpful. For example, com-
paring cognitive functioning between the following groups may
identify the moderating factors: a matched healthy control group,
a matched cancer control group (diagnosed, but not treated),
and treated breast cancer groups (surgery only, chemotherapy
only, chemotherapy and hormonal therapy, and hormonal therapy
only).
No consistent association between psychological factors (i.e.,
depression, anxiety, or fatigue) and performance on objective mea-
sures of cognitive functioning has been found (7, 8). Some studies
have even reported that depression and fatigue were significantly
related to subjective, but not objective cognitive complaints (5, 36).
However, the lack of association between psychological factors and
post-chemotherapy cognitive impairment among breast cancer
patients may be due partly to the issue of ecological validity of the
objective measures (42). In addition, breast cancer patients with
depression have typically been excluded from studies (5, 8, 17, 18,
20–24, 27, 31–36), or these factors were statistically controlled for
(7, 26, 38). It is also possible that depressed breast cancer patients
are less likely to participate in research. Hence, the relationship
between mental health issues and post-chemotherapy cognitive
impairment remains unclear, and this needs to be examined in
future research.
Finally, it may be important to measure additional cognitive
domains. For example, further subdivision of some cognitive
domains may help identifying specific cognitive functions that are
vulnerable to the process (diagnosis, treatment, and recovery) of
breast cancer and, this would consequently help clinicians provid-
ing patients with focused intervention. More specifically, executive
function may be subdivided into working memory, inhibition,
and shifting, while attention may be subdivided into attention
span, selective attention, and focused attention. Furthermore, an
investigation of cognitive domains that have not included in pre-
vious studies would also be beneficial. For instance, impairments
in prospective memory, or the ability to remember what to do in
future, would have significant clinical implications.
CONCLUSION
The effects of chemotherapy on cognitive functioning among
breast cancer patients were found to be subtle, but relatively
global with five of eight domains being impaired. These find-
ings indicate that some cognitive domains are more (e.g., pro-
cessing speed) or less (e.g., long-term memory) susceptible to
chemotherapy than others. Further, particular cognitive domains
(e.g., long-term memory) may show greater improvement over
time than others albeit these domains may be susceptible to prac-
tice effects. Because individuals’ levels of cognitive performance
at pre-chemotherapy assessment may not be the same as their
pre-diagnosis performance, it remains unclear whether, and to
what degree post-chemotherapy cognitive decline in breast can-
cer patients improves or persists. A significant level of cognitive
impairment was observed in breast cancer patients previously
treated with chemotherapy, as compared to healthy controls. How-
ever, level of cognitive impairment in chemotherapy patients
did not significantly differ from breast cancer patients without
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chemotherapy. Hence, cognitive impairment may be common
among breast cancer patients irrespective of their treatment reg-
imens. Furthermore, patient characteristics (age and educational
level) and the processes of cancer diagnosis and treatment may
moderate the magnitude of cognitive impairment. This is the first
review that examined and found the moderating effect of the type
of control groups in cross-sectional studies. Future prospective
longitudinal research is warranted to examine the degree and per-
sisting nature of cognitive impairment present after chemotherapy,
with comparisons made to participants’ cognitive function prior to
diagnosis. Accurate understanding of the effects of chemotherapy
is essential to enable informed decisions regarding treatment and
to improve quality of life among breast cancer patients.
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